Abdul Aziz Mohammad Firdaus, Mohd Yusof Aimi Nadia
Centre for Law and Ethics in Science and Technology (CELEST), Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia.
Medical Ethics and Law Unit, Faculty of Medicine, Universiti Teknologi MARA (UiTM), Shah Alam, Selangor Malaysia.
Asian Bioeth Rev. 2019 May 25;11(2):209-222. doi: 10.1007/s41649-019-00086-2. eCollection 2019 Jun.
As with many other countries, Malaysia is also developing and promoting biomedical research to increase the understanding of human diseases and possible interventions. To facilitate this development, there is a significant growth of biobanks in the country to ensure continuous collection of biological samples for future research, which contain extremely important personal information and health data of the participants involved. Given the vast amount of samples and data accumulated by biobanks, they can be considered as reservoirs of precious biomedical big data. It is therefore imperative for biobanks to have in place regulatory measures to ensure ethical use of the biomedical big data. Malaysia has yet to introduce specific legislation for the field of biobanking. However, it can be argued that its existing Personal Data Protection Act 2010 (PDPA) has laid down legal principles that can be enforced to protect biomedical big data generated by the biobanks. Consent is a mechanism to enable data subjects to exercise their autonomy by determining how their data can be used and ensure compliance with legal principles. However, there are two main concerns surrounding the current practice of consent in biomedical big data in Malaysia. First, it is uncertain that the current practice would be able to respect the underlying notion of autonomy, and second, it is not in accordance with the legal principles of the PDPA. Scholars have deliberated on different strategies of informed consent, and a more interactive approach has recently been introduced: dynamic consent. It is argued that a dynamic consent approach would be able to address these concerns.
与许多其他国家一样,马来西亚也在发展和推广生物医学研究,以增进对人类疾病的了解以及探索可能的干预措施。为推动这一发展,该国的生物样本库数量大幅增加,以确保持续收集生物样本用于未来研究,这些样本包含了参与研究人员极其重要的个人信息和健康数据。鉴于生物样本库积累了大量的样本和数据,它们可被视为珍贵的生物医学大数据库。因此,生物样本库必须制定监管措施,以确保生物医学大数据的合理使用。马来西亚尚未出台生物样本库领域的具体立法。然而,可以认为其现行的2010年《个人数据保护法》(PDPA)已经制定了可实施的法律原则,以保护生物样本库产生的生物医学大数据。同意是一种机制,使数据主体能够通过决定其数据的使用方式来行使自主权,并确保符合法律原则。然而,围绕马来西亚生物医学大数据目前的同意做法存在两个主要问题。第一,目前的做法是否能够尊重自主权这一基本概念尚不确定;第二,它不符合《个人数据保护法》的法律原则。学者们已经探讨了不同的知情同意策略,最近引入了一种更具互动性的方法:动态同意。有人认为,动态同意方法能够解决这些问题。